By: David F., New York
For most of the past 20 years, Medicare Part D has given me and millions of other Americans peace of mind that the medicines our doctors prescribed would be there when we needed them.
Part D has been one of Medicare’s most successful additions. Today, approximately 56 million Americans rely on it for prescription drug coverage. The program was built around competition and choice, giving beneficiaries options and allowing plans to compete for enrollment. For patients like me, that has translated into reliable access to medicines that help us stay healthier, avoid complications and remain independent.
As a senior, and a retired medical provider, I’ve seen these benefits firsthand.
The medicines my friends, former patients, and I take help manage chronic health conditions and maintain our quality of life. Because of Part D, I am able to work with my doctor to find treatments that are right for me without constantly wondering how I can afford them. For seniors on fixed incomes that stability matters.
That’s why I’ve been paying close attention to the changes happening to Part D. Since passage of the Inflation Reduction Act (IRA), the program has undergone one of the most significant overhauls in its history. While these changes were intended to help patients, many have had the opposite effect. Our premiums have gone up and navigating the program has become more complicated than it used to be.
The trends we’re seeing today – fewer plans, more restrictions and higher costs for some beneficiaries – aren’t happening in a vacuum. They’re emerging as more significant changes could be on the horizon.
As a patient and former health care provider, it makes me nervous when I hear policymakers discussing proposals like Most Favored Nation (MFN) price controls that would significantly alter the program even further. My concern isn’t theoretical. Part D has worked for two decades because it has balanced affordability, competition and patient choice. When policymakers make dramatic changes to that balance, patients often feel the effects in ways that aren’t immediately obvious – through higher premiums, fewer plan options, more utilization management tools, or greater uncertainty about whether a medicine will be covered.
I worry that MFN could add even more pressure to a program that is already undergoing substantial change. Patients don’t experience health policy debates through headlines or talking points – we experience them when we sit down during open enrollment and discover our premiums have increased or the medicine our doctor prescribed is now harder to access.
As Part D enters its third decade, I hope policymakers remember what has made the program successful. For 20 years, it has helped millions of seniors like me and people with disabilities, access the medicines they need through a system built on competition, choice and patient-centered coverage.
Patients don’t need more uncertainty. We need a Medicare drug benefit that remains affordable, predictable and focused on helping us get the treatments our doctors recommend. Twenty years after Part D’s creation, that’s still the standard policymakers should be striving to meet.
